DrugsDrug TherapyInvestigationalProstatic NeoplasmThe standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18聽months of androgen deprivation ...
"We have very strong data that both these drugs suppress tumor progression in advanced treatment-resistant prostate cancer and, importantly, inflammation," Dr. Philp said. "ARDS is a rapid-onset life-threatening respiratory failure triggered by infection, and the root cause of COVID-19-related de...
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0 Keck Medicine of the University of Southern California (USC) scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a new...
Investigational New Drugs is a forum for rapid dissemination of information on new anticancer agents. The journal publishes original articles dealing with ...
New drugs in prostate cancerArmstrong, Andrew J.; Carducci, Michael A.Abstract Purpose of review: The survival of hormone-refractory metastatic prostate cancer patients has improved with the use of docetaxel-based chemotherapy. The survival benefits, however, are modest suggesting that rationally ...
are now being used earlier, in settings including nonmetastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. This puts physicians in a position where there is uncertainty of how to treat when their patients relapse after treatment since these drugs are not curat...
Over the past decade, molecular-targeted therapies have been added to cytotoxic and anti-endocrine drugs in the treatment of cancer, with the aim to target... DD Rosa,G Ismael,LD Lago,... - 《Cancer Treatment Reviews》 被引量: 312发表: 2008年 Developing an International Assurance Standard ...
Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminars in OncologyRaghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin ... D Raghavan - 《Seminars in...
of these coregulators in modulating GR and AR target gene expression. Importantly, the findings of this thesis revealed target gene-dependent role of coregulators in GR and AR signaling and provided insights for designing and developing new drugs to treat inflammatory diseases and prostate cancer. ...
" could lead to a more efficient therapeutic approach for the treatment of castration-resistant prostate cancer. "Abiraterone, a CYP17A1 inhibitor, has been one the biggest breakthough drugs to combat advanced cancer. But resistance to this drug is still a major problem. Having a second line ...